Diabetes Research and Clinical Practice
Volume 83, Issue 1 , Pages 54-60 , January 2009

Rosiglitazone preserves islet β-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study

  • Zhifang Yang

      Affiliations

    • Diabetes Center, Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, Changsha, China
    • The Department of Endocrinology, First Affiliated Hospital of Nanchang University, Nanchang, China
    • ,
  • Zhiguang Zhou

      Affiliations

    • Diabetes Center, Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, Changsha, China
    • Corresponding Author InformationCorresponding author.
    • ,
  • Xia Li

      Affiliations

    • Diabetes Center, Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, Changsha, China
    • ,
  • Gan Huang

      Affiliations

    • Diabetes Center, Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, Changsha, China
    • ,
  • Jian Lin

      Affiliations

    • Diabetes Center, Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, Changsha, China

Received 10 April 2008 ,Revised 19 September 2008 ,Accepted 23 September 2008.

References 

  1. Pozzilli P, Mario U-Di. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of adults): definition, characterization, and potential prevention. Diabetes Care. 2001;24:1460–1467
  2. Gianani R, Pugliese A, Bonner-Weir S, Shiffrin AJ, Soeldner JS, Erlich H, et al. Prognostically significant heterogeneity of cytoplasmic islet cell antibodies in relatives of patients with type I diabetes. Diabetes. 1992;41:347–353
  3. Hagopian WA, Karlsen AE, Gottsäter A, Landin-Olsson M, Grubin CE, Sundkvist G, et al. Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 64K autoantibody positivity at onset predicts diabetes type. J. Clin. Invest. 1993;91:368–374
  4. Groop L, Tuomi T, Rowley M, Zimmet P, Mackay IR. Latent autoimmune diabetes in adults (LADA)-more than a name. Diabetologia. 2006;49:1996–1998
  5. Lohmann T, Kellner K, Verlohren HJ, Krug J, Steindorf J, Scherbaum WA, et al. Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA). Diabetologia. 2001;44:1005–1010
  6. Borg H, Gottsäter A, Landin-Olsson M, Fernlund P, Sundkvist G. High levels of antigen-specific islet antibodies predict future beta-cell failure in patients with onset of diabetes in adult age. J. Clin. Endocrinol. Metab. 2001;86:3032–3038
  7. Maruyama T, Shimada A, Kanatsuka A, Kasuga A, Takei I, Yokoyama J, et al. Multicenter prevention trials of slowly progressive type 1 diabetes with small dose of insulin (the Kyoto study): preliminary report. Ann. N. Y. Acad. Sci. 2003;1005:362–369
  8. Behme MT, Dupre J, Harris SB, Hramiak IM, Mahon JL. Insulin resistance in latent autoimmune diabetes of adulthood. Ann. N. Y. Acad. Sci. 2003;1005:374–377
  9. Beales PE, Pozzilli P. Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes. Diabetes Metab. Res. Rev. 2002;18:114–117
  10. Zhou Z, Li X, Huang G, Peng J, Yang L, Yan X, et al. Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA). Diabetes Metab. Res. Rev. 2005;21:203–208
  11. Li X, Zhou ZG, Huang G, Yan X, Yang L, Chen XY, et al. Optimal cutoff point of glutamate decarboxylase antibody titers in differentiating two subtypes of adult-onset latent autoimmune diabetes. Ann. N. Y. Acad. Sci. 2004;1037:122–126
  12. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27:1487–1495
  13. Beales PE, Giorgini A, Annovazzi A, Signore A, Parlapiano C, Pozzilli P. Metformin does not alter diabetes incidence in the NOD mouse. Horm. Metab. Res. 1997;29:261–263
  14. J.P. Palmer, G.A. Fleming, C.J. Greenbaum, K.C. Herold, L.D. Jansa, H. Kolb, J.M. Lachin, K.S. Polonsky, P. Pozzilli, J.S. Skyler, M.W. Steffes, C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21–22 October 2001, Diabetes 53 (2004) 250–264.
  15. Shimada A, Imazu Y, Morinaga S, Funae O, Kasuga A, Atsumi Y, et al. T-cell insulitis found in anti-GAD65+ diabetes with residual β-cell function. Diabetes Care. 1999;22:615–617
  16. Fourlanos S, Dotta F, Greenbaum CJ, Palmer JP, Rolandsson O, Colman PG, et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia. 2005;48:2206–2212
  17. Leslie RD, Williams R, Pozzilli P. Type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow. J Clin Endocrinol Metab. 2006;91:1654–1659
  18. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. ADOPT Study Group Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427–2443
  19. Carlsson S, Midthjell K, Tesfamarian MY, Grill V. Age, overweight and physical inactivity increase the risk of latent autoimmune diabetes in adults: results from the Nord-Trøndelag health study. Diabetologia. 2007;50:55–58
  20. Chiu HK, Tsai EC, Juneja R, Stoever J, Brooks-Worrell B, Goel A, et al. Equivalent insulin resistance in latent autoimmune diabetes in adults (LADA) and type 2 diabetic patients. Diabetes Res Clin Pract. 2007;77:237–244
  21. Carlsson A, Sundkvist G, Groop L, Tuomi T. Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA). J Clin Endocrinol Metab. 2000;85:76–80
  22. Kamiya H, Zhang W, Ekberg K, Wahren J, Sima AA. C-Peptide reverses nociceptive neuropathy in type 1 diabetes. Diabetes. 2006;55:3581–3587
  23. Rebsomen L, Pitel S, Boubred F, Buffat C, Feuerstein JM, Raccah D, et al. C-peptide replacement improves weight gain and renal function in diabetic rats. Diabetes Metab. 2006;32:223–228
  24. Yang XY, Wang LH, Chen T, Hodge DR, Resau JH, DaSilva L, et al. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem. 2000;275:4541–4544
  25. Wang P, Anderson PO, Chen S, Paulsson KM, Sjögren HO, Li S. Inhibition of the transcription factors AP-1 and NF-kappaB in CD4 T cells by peroxisome proliferator-activated receptor gamma ligands. Int Immunopharmacol. 2001;1:803–812
  26. Brusko TM, Wasserfall CH, Clare-Salzler MJ, Schatz DA, Atkinson MA. Functional defects and the influence of age on the frequency of CD4+CD25+ T-cells in type 1 diabetes. Diabetes. 2005;54:1407–1414
  27. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes. 2005;54:92–99
  28. Yang Z, Zhou Z, Huang G, Ling H, Yan X, Peng J, et al. The CD4(+) regulatory T-cells is decreased in adults with latent autoimmune diabetes. Diabetes Res Clin Pract. 2007;76:126–131
  29. Wohlfert EA, Nichols FC, Nevius E, Clark RB. Peroxisome proliferator-activated receptor gamma (PPARgamma) and immunoregulation: enhancement of regulatory T cells through PPARgamma-dependent and -independent mechanisms. J Immunol. 2007;178:4129–4135
  30. Hontecillas R, Bassaganya-Riera J. Peroxisome proliferator-activated receptor gamma is required for regulatory CD4+ T cell-mediated protection against colitis. J Immunol. 2007;178:2940–2949
  31. Lundsgaard D, Holm TL, Hornum L, Markholst H. In Vivo control of diabetogenic T-cells by regulatory CD4+CD25+ T-cells expressing Foxp3. Diabetes. 2005;54:1040–1047

PII: S0168-8227(08)00456-7

doi: 10.1016/j.diabres.2008.09.044

Diabetes Research and Clinical Practice
Volume 83, Issue 1 , Pages 54-60 , January 2009

Article Tools

* Image Usage & Resolution